cholesterol

Subscribe to RSS - cholesterol

Specialty Pharmacy Continuum: UMass Medical School pharmacist says delay in data on new cholesterol-lowering drugs frustrating for prescribers

A UMass Medical School pharmacy expert says the delay in the results of a trial on proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors is frustrating for prescribers waiting to give the drugs to patients with uncontrolled cholesterol levels, according to an article in Specialty Pharmacy Continuum.

Pharmacy Practice News: UMass Medical School pharmacist says providers will wait for more data before prescribing new cholesterol-lowering drugs

A UMass Medical School pharmacy expert believes providers will wait for the results of more cardiovascular outcomes trials before prescribing proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors to manage their patients’ cholesterol levels, according to an article in Pharmacy Practice News.

Specialty Pharmacy Continuum: UMass Medical School pharmacist says PCSK9 value-based contracts will make them more affordable and put focus on adherence

A UMass Medical School clinical consultant pharmacist says value-based contracts for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, a new class of cholesterol-lowering drugs, will lead to lower prices and help patients decrease cholesterol levels, according to an article in Specialty Pharmacy Continuum about an agreement Cigna has reached with Amgen and Sanofi/Regeneron.

UMass Medical School pharmacy expert to present on the potential use of PCSK9 inhibitors for managing cholesterol at Asembia specialty pharmacy summit

A UMass Medical School pharmacy expert will present on proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and their potential use for managing cholesterol at Asembia's 2016 Armada Specialty Pharmacy Summit May 2-6 in Las Vegas.